Predicting the Success of HPV Vaccines

Predicting the Success of HPV Vaccines

October 25, 2005

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-10-25-2005

Volume 0

Issue 0

Will vaccines against cervical cancer be the blockbusters that Merck and GSK are predicting? Or will issues of cost-effectiveness and parental reluctance hold them back? The experts weigh in on the debate.

Articles in this issue

Atypical Antipsychotics Increase Risk of Death for Dementia Patients

Predicting the Success of HPV Vaccines

Advisory Committee to Review OTC HIV Test

Related Content

Emerging Biopharma Launches: Strategizing in Today’s Global Market

Mike Hollan

March 13th 2025

Article

A look at the current landscape and how young companies can set the stage for product launch.

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs

February 18th 2025

Podcast

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.

Pre-Launch Prep for Emerging Biopharmas: Data First, Then the Rest

Todd Foster;Yair Markovits

March 13th 2025

Article

Making early commercial data and analytics decisions for launch cen future-proof their data management.

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Miranda Schmalfuhs

February 10th 2025

Podcast

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.

Phase III Trial Data Show Vepdegestrant Produces Encouraging Outcomes in ER+/HER2- Advanced or Metastatic Breast Cancer

Don Tracy, Associate Editor

March 13th 2025

Article

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+/HER2- advanced or metastatic breast cancer.